Medikamenteninfusion Injektion
Originaltitel der Bekanntmachung
Norway – Medical equipments, pharmaceuticals and personal care products – 2801c Medicines infusion injection
Opportunity Score
Warum diese Bewertung?
Chance
54 / 100
Komplexität
60 / 100
Risikofaktoren
The available data does not include the detailed procurement documents, product specifications, pricing templates, fram...
No estimated value or framework maximum value is disclosed, making pricing strategy, capacity planning, and expected op...
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Eckdaten der Ausschreibung
- Öffentlicher Auftraggeber
- SYKEHUSINNKJØP HF
- Land
- Norwegen
- CPV
- 33000000 - Medical equipments, pharmaceuticals and personal care products +1 weitere
- Frist
- Sep 17, 2026
Überblick
Moderate opportunityWichtige Fakten
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jan 2030
- Supply of various medicines for use in infusion injections.
- Performance location: Norway.
Vollständige Zusammenfassung anzeigen
Open procedure for a framework agreement covering various medicines for infusion injections in Norway. The structured data identifies one lot, mandatory electronic submission, Norwegian language, and a submission deadline of 17 September 2026 at 10:00. Procurement documents appear available through the Ivalua portal, but the underlying procurement documents were not provided or analyzed. Contract value, selection criteria, and award criteria are missing. The structured data also conflicts with the XML notice on EU funding status.
Risiken
The available data does not include the detailed procurement documents, product specifications, pricing templates, fram...
No estimated value or framework maximum value is disclosed, making pricing strategy, capacity planning, and expected op...
Analyse kann unvollständig sein
Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.
Wichtige Anforderungen
Technical
- Open procedure.
- Supply contract for medicinal products.
Administrative
- Electronic submission is required through the specified Ivalua portal.
Zuschlagskriterien
Lot 1
Auftraggeber
Ort
Vadsø, NOR
Auftraggeberprofil
Kennung
916879067
Tätigkeit
Health
Lose (1)
LOT-0001
Medicines for Infusion and Injection
Supply of various medicines intended for use in infusion injections in Norway. The lot is identified as a framework agreement with a planned period from 1 February 2028 to 31 January 2030. Detailed product requirements and commercial conditions are not available in the provided data.
Ort
Dauer
Kategorie
Zuschlagskriterien
Frist
Zuschlagsdetails
Sykehusinnkjøp HF, division Pharmaceuticals, shall procure various medicines for use in infusion injections. The contracting authorities for this competition are the four regional health authorities in Norway, Helse Sør-Øst RHF, Helse Vest RHF, Helse Midt-Norway RHF and Helse Nord RHF.
Zusätzliche CPV-Codes
Hinweis zum Wert
Originale TED-Daten anzeigen
Originaler Los-Titel
2801c Medicines infusion injection
Originale TED-Beschreibung
Sykehusinnkjøp HF, division Pharmaceuticals, shall procure various medicines for use in infusion injections. The contracting authorities for this competition are the four regional health authorities in Norway, Helse Sør-Øst RHF, Helse Vest RHF, Helse Midt-Norway RHF and Helse Nord RHF.
Vergabedetails
- Veröffentlichungsdatum
- 23 Jun 2026
- Sprachen
- English, Norwegian
Referenzmetadaten
- Rechtsgrundlage
- 32014L0024
Referenz-IDs
- Ausschreibungs-ID
- 431517-2026
Dokumente (1)
Ähnliche Ausschreibungen
Poland – Various medicinal products – Dostawa produktów leczniczych
Slovenia – Various medicinal products – Sukcesivna dobava zdravil za obdobje štirih let
Portugal – Various medicinal products – Aquisição de bens e medicamentos para a área de oftalmologia
Norway – Pharmaceutical products – Medicines and multi-dose Narvik kommune - Framework agreement
Belgium – Various medicinal products – Biosimilars: Infliximab IV, Tocilizumab IV en SC, Denosumab SC en Epoëtine alfa
Poland – Pharmaceutical products – Dostawa produktów leczniczych - część nr 2
Opportunity Score
Warum diese Bewertung?
Chance
54 / 100
Komplexität
60 / 100
Risikofaktoren
The available data does not include the detailed procurement documents, product specifications, pricing templates, fram...
No estimated value or framework maximum value is disclosed, making pricing strategy, capacity planning, and expected op...
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications